piritramide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
3478 302-41-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • piritramide
  • dipidolor
  • dipiritramide
  • pirdolan
  • piridolan
  • pirinitramide
A diphenylpropylamine with intense narcotic analgesic activity of long duration. It is a derivative of MEPERIDINE with similar activity and usage.
  • Molecular weight: 430.60
  • Formula: C27H34N4O
  • CLOGP: 3.19
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 73.36
  • ALOGS: -4.63
  • ROTB: 7

Drug dosage:

DoseUnitRoute
45 mg P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 4.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MET,NTRK2,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1,TTK 38
kinase-selectivity-class AXL,EPHB4,ERBB2,FLT3,GRK2,PDK4,SIK2,SIK3,STK33 9
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 108.26 32.61 37 2056 32491 90593863
Stevens-Johnson syndrome 73.31 32.61 27 2066 29349 90597005
Patent ductus arteriosus 69.57 32.61 17 2076 4552 90621802
Basal ganglion degeneration 67.45 32.61 11 2082 371 90625983
Anaesthesia 65.31 32.61 11 2082 453 90625901
Tissue infiltration 58.41 32.61 11 2082 859 90625495
Congenital central hypoventilation syndrome 56.28 32.61 7 2086 29 90626325
Inguinal hernia 54.23 32.61 12 2081 2086 90624268
Uterine enlargement 53.60 32.61 11 2082 1337 90625017
Psychogenic seizure 49.19 32.61 11 2082 2005 90624349
Renal cyst 48.03 32.61 16 2077 12934 90613420
Neurological decompensation 43.15 32.61 11 2082 3490 90622864
Hypochromic anaemia 43.03 32.61 10 2083 2161 90624193
Monoplegia 42.63 32.61 11 2082 3663 90622691
Hyperventilation 40.35 32.61 12 2081 6716 90619638
Dysaesthesia 38.73 32.61 11 2082 5244 90621110
Intervertebral disc disorder 38.31 32.61 11 2082 5449 90620905
Abdominal tenderness 36.49 32.61 12 2081 9312 90617042
Hyperpyrexia 35.24 32.61 10 2083 4751 90621603
Premature baby 34.44 32.61 15 2078 25062 90601292

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood pressure measurement 67.54 40.34 10 910 190 42620225
Weight bearing difficulty 49.25 40.34 10 910 1238 42619177
Motor developmental delay 42.10 40.34 8 912 703 42619712

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperventilation 80.94 36.73 22 2538 8925 110577814
Toxic epidermal necrolysis 71.68 36.73 32 2528 56695 110530044
Stevens-Johnson syndrome 67.51 36.73 29 2531 46872 110539867
Basal ganglion degeneration 65.97 36.73 11 2549 425 110586314
Anaesthesia 62.38 36.73 11 2549 593 110586146
Blood pressure measurement 57.07 36.73 10 2550 520 110586219
Uterine enlargement 57.01 36.73 11 2549 974 110585765
Tissue infiltration 56.39 36.73 11 2549 1032 110585707
Congenital central hypoventilation syndrome 56.26 36.73 7 2553 29 110586710
Hypochromic anaemia 54.28 36.73 13 2547 3188 110583551
Psychogenic seizure 47.42 36.73 11 2549 2353 110584386
Inguinal hernia 42.93 36.73 13 2547 7712 110579027
Monoplegia 39.44 36.73 11 2549 4898 110581841
Intervertebral disc disorder 38.18 36.73 11 2549 5501 110581238
Weight bearing difficulty 37.84 36.73 10 2550 3641 110583098
Speech disorder 36.99 36.73 21 2539 61548 110525191

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02AC03 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Diphenylpropylamine derivatives
MeSH PA D000700 Analgesics
MeSH PA D000701 Analgesics, Opioid
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D009294 Narcotics
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35480 analgesic

Related Drugs by ATC class:

N02AC Diphenylpropylamine derivatives 4 drugs
bezitramidedextromoramidedextropropoxyphenemethadone

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.07 Basic
pKa2 6.0 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000167338 NUI
D07288 KEGG_DRUG
C0031982 UMLSCUI
CHEBI:135699 CHEBI
CHEMBL559288 ChEMBL_ID
DB12492 DRUGBANK_ID
9331 PUBCHEM_CID
1343 INN_ID
4RP92LYZ2F UNII
8354 RXNORM
006892 NDDF
707837002 SNOMEDCT_US
D010892 MESH_DESCRIPTOR_UI

Pharmaceutical products:

None